GSK Pharma Q4 PAT seen up 15% to Rs 123 cr

Healthcare company GlaxoSmithKline Pharmaceuticals (GSK Pharma) is set to report a profit after tax (PAT) of Rs 123 crore for the quarter ended December 2010, up 15% as compared to Rs 107.2 crore in same quarter the previous year, according to CNBC-TV18 estimates.

Revenue is seen going up by 22.4% to Rs 510.4 crore from Rs 417 crore (YoY). Earning before interest, tax, depreciation and amortisation (EBITDA) is likely to go up by 26% to Rs 153 crore from Rs 122 crore (YoY). Operating profit margin is seen improving marginally at 30% versus 29%. For the year calendar year 2010, revenues are expected to go up by 14% to Rs 1,891.1 crore from Rs 2,154 crore and EBITDA is likely to go up by 8.8% to Rs 734 crore from Rs 675 crore. Operating profit margin is seen declining at 34% versus 35.7%. PAT is seen going up by 8.4% to Rs 555 crore from Rs 512.29 crore (YoY).